UK markets close in 1 hour 11 minutes
  • FTSE 100

    7,086.28
    -23.67 (-0.33%)
     
  • FTSE 250

    22,679.73
    -76.60 (-0.34%)
     
  • AIM

    1,190.45
    -0.06 (-0.01%)
     
  • GBP/EUR

    1.1748
    -0.0035 (-0.30%)
     
  • GBP/USD

    1.3357
    +0.0045 (+0.34%)
     
  • BTC-GBP

    44,178.13
    +1,294.29 (+3.02%)
     
  • CMC Crypto 200

    1,499.13
    +56.35 (+3.91%)
     
  • S&P 500

    4,639.81
    -15.46 (-0.33%)
     
  • DOW

    34,902.97
    -232.97 (-0.66%)
     
  • CRUDE OIL

    67.92
    -2.03 (-2.90%)
     
  • GOLD FUTURES

    1,808.20
    +23.00 (+1.29%)
     
  • NIKKEI 225

    27,821.76
    -462.16 (-1.63%)
     
  • HANG SENG

    23,475.26
    -376.98 (-1.58%)
     
  • DAX

    15,215.24
    -65.62 (-0.43%)
     
  • CAC 40

    6,748.13
    -28.12 (-0.41%)
     

3 Biotech Stocks That Are Ridiculously Overpriced

·6-min read
3 Biotech Stocks That Are Ridiculously Overpriced

Beauty is in the eye of the beholder -- and, in many cases, so is the appropriate valuation of a stock. Here's why they picked Cassava Sciences (NASDAQ: SAVA), Ocugen (NASDAQ: OCGN), and Moderna (NASDAQ: MRNA). Prosper Junior Bakiny (Cassava Sciences): Investors have been flocking to this clinical-stage biotech all year long, pushing its share price up by well over 600%.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting